title: Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.
authors.affiliation: Instituto de Estudios de Mastocitosis de Castilla La Mancha, Hospital Virgen del Valle, Toledo, Spain.
authors.forename: Iván
authors.initials: I
authors.lastname: Alvarez-Twose
authors.forename: Pablo
authors.initials: P
authors.lastname: González
authors.forename: José Mário
authors.initials: JM
authors.lastname: Morgado
authors.forename: María
authors.initials: M
authors.lastname: Jara-Acevedo
authors.forename: Laura
authors.initials: L
authors.lastname: Sánchez-Muñoz
authors.forename: Almudena
authors.initials: A
authors.lastname: Matito
authors.forename: Manuela
authors.initials: M
authors.lastname: Mollejo
authors.forename: Alberto
authors.initials: A
authors.lastname: Orfao
authors.forename: Luis
authors.initials: L
authors.lastname: Escribano
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D008297:Male; D034721:Mastocytosis, Systemic / Q000188:drug therapy* / Q000473:pathology*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D035583:Rare Diseases; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate